• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDX
Click for more information
0.00% 15.0¢

CARDIEX LIMITED - Announcements

Market Cap $17.65M  ! watchlist Created with Sketch. Add to my watchlist

CardieX Limited is an Australia-based digital health technology company. The Company... CardieX Limited is an Australia-based digital health technology company. The Company develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. It specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Company’s SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDX Appendix 3B18/03/15
CDX Change in substantial holding13/03/15
CDX Appendix 3B12/03/15
CDX Teleconference details10/03/15
CDX AMA accepts recommendation for category 1 CPT codePRICE SENSITIVE10/03/15
CDX AtCor reports first half profit23/02/15
CDX Half Yearly Report and AccountsPRICE SENSITIVE23/02/15
CDX Tax refundPRICE SENSITIVE22/01/15
CDX +Becoming a substantial holder from OCP04/12/14
CDX +Becoming a substantial holder from OCP04/12/14
CDX Appendix 3B03/12/14
CDX Cleansing statement28/11/14
CDX +Successful share placementPRICE SENSITIVE28/11/14
CDX Trading HaltPRICE SENSITIVE27/11/14
CDX Results of Meeting31/10/14
CDX Chairmans address to AGM31/10/14
CDX Investor presentation24/10/14
CDX SphygmoCor selected for US publicly funded studyPRICE SENSITIVE07/10/14
CDX Annual Report to shareholders30/09/14
CDX Notice of Annual General Meeting/Proxy Form30/09/14
CDX Change in substantial holding12/09/14
CDX SphygmoCor selected for French Alzheimers trialPRICE SENSITIVE03/09/14
CDX App 4E / Full Year Statutory AccountsPRICE SENSITIVE28/08/14
CDX Market updatePRICE SENSITIVE03/07/14
CDX AtCor and SunTech launch innovative ABPM for Central BPPRICE SENSITIVE18/06/14
CDX First SphygmoCor sales in ChinaPRICE SENSITIVE02/06/14
CDX Investor presentation01/05/14
CDX Patent grant in USAPRICE SENSITIVE16/04/14
CDX Study shows improved outcomes from SphygmoCor guided therapyPRICE SENSITIVE03/04/14
CDX Change in substantial holding07/03/14
CDX 1H FY2014 results20/02/14
CDX Half Yearly Report and AccountsPRICE SENSITIVE20/02/14
CDX SphygmoCor XCEL approved for sale in CanadaPRICE SENSITIVE30/01/14
CDX +Ceasing to be a substantial holder from ALF14/01/14
CDX SphygmoCor XCEL approved for sale in ChinaPRICE SENSITIVE14/01/14
CDX Market updatePRICE SENSITIVE09/01/14
CDX Appendix 3B08/01/14
CDX +Change in substantial holding from ALF06/01/14
CDX Meta-analysis finds improved cardiovascular risk prediction12/12/13
CDX Appendix 3B03/12/13
CDX +Change in substantial holding from ALF02/12/13
CDX ASX Price Query & ResponsePRICE SENSITIVE12/11/13
CDX Change of Director's Interest Notice08/11/13
CDX Change of Director's Interest Notice05/11/13
CDX Appendix 3B05/11/13
CDX Results of Meeting01/11/13
CDX Appendix 3B31/10/13
CDX Chairmans address to shareholders31/10/13
CDX Investor presentation28/10/13
CDX US$0.6 million new pharmaceutical trial contractPRICE SENSITIVE28/10/13
CDX Mexico registration update25/10/13
CDX Appendix 4C - quarterlyPRICE SENSITIVE23/10/13
CDX Change of Director's Interest Notice x 422/10/13
CDX +Change in substantial holding from ALF09/10/13
CDX XCEL rated excellent according to European guidelines02/10/13
CDX Appendix 3B01/10/13
CDX Change of Director's Interest Notice30/09/13
CDX Annual Report to shareholders30/09/13
CDX Notice of Annual General Meeting/Proxy Form30/09/13
CDX Aust study demonstrates the benefits of measuring central BPPRICE SENSITIVE26/09/13
CDX SphygmoCor XCEL approved for sale in MexicoPRICE SENSITIVE04/09/13
CDX Preliminary Final Report & Annual AccountsPRICE SENSITIVE30/08/13
CDX AtCor reports $2.7 million maiden profit for FY201330/08/13
CDX Half Yearly Report and AccountsPRICE SENSITIVE30/08/13
CDX Appendix 3B22/08/13
CDX SphygmoCor XCEL approved for sale in Republic of KoreaPRICE SENSITIVE07/08/13
CDX Seminal study for central pressures in clinical practicePRICE SENSITIVE01/08/13
CDX Investor Presentation22/07/13
CDX AtCor to report full year maiden profitPRICE SENSITIVE22/07/13
CDX Appendix 4C - quarterlyPRICE SENSITIVE22/07/13
CDX Patent granted in EuropePRICE SENSITIVE15/07/13
CDX Shareholder Update23/05/13
CDX Appendix 4C - quarterlyPRICE SENSITIVE23/04/13
CDX New study strongly supports measurement of central pressuresPRICE SENSITIVE19/04/13
CDX Ceasing to be a substantial holder04/03/13
CDX Change in substantial holding04/03/13
CDX US$0.8million pharmaceutical trial contract expansionPRICE SENSITIVE25/02/13
CDX AtCor reports $2.3 million profit for H1 FY210321/02/13
CDX Half Yearly Report and AccountsPRICE SENSITIVE21/02/13
CDX AtCor to report profit for H1 FY2013PRICE SENSITIVE31/01/13
CDX Appendix 4C - quarterlyPRICE SENSITIVE22/01/13
CDX Tax refundPRICE SENSITIVE18/12/12
CDX US$350,000 order for publicly funded studyPRICE SENSITIVE05/12/12
CDX SphygmoCor XCEL receives US FDA clearancePRICE SENSITIVE20/11/12
CDX Change of Director's Interest Notice15/11/12
CDX Change of Director's Interest Notice31/10/12
CDX Appendix 3B31/10/12
CDX Change in substantial holding30/10/12
CDX Results of Meeting26/10/12
CDX Chairmans address to 2012 AGM26/10/12
CDX Investor Presentation22/10/12
CDX Appendix 4C - quarterlyPRICE SENSITIVE18/10/12
CDX US$3.2 million pharmaceutical trial contractPRICE SENSITIVE08/10/12
CDX Annual Report to shareholders26/09/12
CDX Notice of Annual General Meeting/Proxy Form26/09/12
CDX New study finds arterial stiffness precedes hypertension21/09/12
CDX Full Year Statutory AccountsPRICE SENSITIVE23/08/12
CDX Change of Director's Interest Notice x 514/08/12
CDX US$1.1 million pharmaceutical contractPRICE SENSITIVE13/08/12
CDX Appendix 3B09/08/12
CDX Appendix 3B
18/03/15
CDX Change in substantial holding
13/03/15
CDX Appendix 3B
12/03/15
CDX Teleconference details
10/03/15
CDX AMA accepts recommendation for category 1 CPT code
10/03/15PRICE SENSITIVE
CDX AtCor reports first half profit
23/02/15
CDX Half Yearly Report and Accounts
23/02/15PRICE SENSITIVE
CDX Tax refund
22/01/15PRICE SENSITIVE
CDX +Becoming a substantial holder from OCP
04/12/14
CDX +Becoming a substantial holder from OCP
04/12/14
CDX Appendix 3B
03/12/14
CDX Cleansing statement
28/11/14
CDX +Successful share placement
28/11/14PRICE SENSITIVE
CDX Trading Halt
27/11/14PRICE SENSITIVE
CDX Results of Meeting
31/10/14
CDX Chairmans address to AGM
31/10/14
CDX Investor presentation
24/10/14
CDX SphygmoCor selected for US publicly funded study
07/10/14PRICE SENSITIVE
CDX Annual Report to shareholders
30/09/14
CDX Notice of Annual General Meeting/Proxy Form
30/09/14
CDX Change in substantial holding
12/09/14
CDX SphygmoCor selected for French Alzheimers trial
03/09/14PRICE SENSITIVE
CDX App 4E / Full Year Statutory Accounts
28/08/14PRICE SENSITIVE
CDX Market update
03/07/14PRICE SENSITIVE
CDX AtCor and SunTech launch innovative ABPM for Central BP
18/06/14PRICE SENSITIVE
CDX First SphygmoCor sales in China
02/06/14PRICE SENSITIVE
CDX Investor presentation
01/05/14
CDX Patent grant in USA
16/04/14PRICE SENSITIVE
CDX Study shows improved outcomes from SphygmoCor guided therapy
03/04/14PRICE SENSITIVE
CDX Change in substantial holding
07/03/14
CDX 1H FY2014 results
20/02/14
CDX Half Yearly Report and Accounts
20/02/14PRICE SENSITIVE
CDX SphygmoCor XCEL approved for sale in Canada
30/01/14PRICE SENSITIVE
CDX +Ceasing to be a substantial holder from ALF
14/01/14
CDX SphygmoCor XCEL approved for sale in China
14/01/14PRICE SENSITIVE
CDX Market update
09/01/14PRICE SENSITIVE
CDX Appendix 3B
08/01/14
CDX +Change in substantial holding from ALF
06/01/14
CDX Meta-analysis finds improved cardiovascular risk prediction
12/12/13
CDX Appendix 3B
03/12/13
CDX +Change in substantial holding from ALF
02/12/13
CDX ASX Price Query & Response
12/11/13PRICE SENSITIVE
CDX Change of Director's Interest Notice
08/11/13
CDX Change of Director's Interest Notice
05/11/13
CDX Appendix 3B
05/11/13
CDX Results of Meeting
01/11/13
CDX Appendix 3B
31/10/13
CDX Chairmans address to shareholders
31/10/13
CDX Investor presentation
28/10/13
CDX US$0.6 million new pharmaceutical trial contract
28/10/13PRICE SENSITIVE
CDX Mexico registration update
25/10/13
CDX Appendix 4C - quarterly
23/10/13PRICE SENSITIVE
CDX Change of Director's Interest Notice x 4
22/10/13
CDX +Change in substantial holding from ALF
09/10/13
CDX XCEL rated excellent according to European guidelines
02/10/13
CDX Appendix 3B
01/10/13
CDX Change of Director's Interest Notice
30/09/13
CDX Annual Report to shareholders
30/09/13
CDX Notice of Annual General Meeting/Proxy Form
30/09/13
CDX Aust study demonstrates the benefits of measuring central BP
26/09/13PRICE SENSITIVE
CDX SphygmoCor XCEL approved for sale in Mexico
04/09/13PRICE SENSITIVE
CDX Preliminary Final Report & Annual Accounts
30/08/13PRICE SENSITIVE
CDX AtCor reports $2.7 million maiden profit for FY2013
30/08/13
CDX Half Yearly Report and Accounts
30/08/13PRICE SENSITIVE
CDX Appendix 3B
22/08/13
CDX SphygmoCor XCEL approved for sale in Republic of Korea
07/08/13PRICE SENSITIVE
CDX Seminal study for central pressures in clinical practice
01/08/13PRICE SENSITIVE
CDX Investor Presentation
22/07/13
CDX AtCor to report full year maiden profit
22/07/13PRICE SENSITIVE
CDX Appendix 4C - quarterly
22/07/13PRICE SENSITIVE
CDX Patent granted in Europe
15/07/13PRICE SENSITIVE
CDX Shareholder Update
23/05/13
CDX Appendix 4C - quarterly
23/04/13PRICE SENSITIVE
CDX New study strongly supports measurement of central pressures
19/04/13PRICE SENSITIVE
CDX Ceasing to be a substantial holder
04/03/13
CDX Change in substantial holding
04/03/13
CDX US$0.8million pharmaceutical trial contract expansion
25/02/13PRICE SENSITIVE
CDX AtCor reports $2.3 million profit for H1 FY2103
21/02/13
CDX Half Yearly Report and Accounts
21/02/13PRICE SENSITIVE
CDX AtCor to report profit for H1 FY2013
31/01/13PRICE SENSITIVE
CDX Appendix 4C - quarterly
22/01/13PRICE SENSITIVE
CDX Tax refund
18/12/12PRICE SENSITIVE
CDX US$350,000 order for publicly funded study
05/12/12PRICE SENSITIVE
CDX SphygmoCor XCEL receives US FDA clearance
20/11/12PRICE SENSITIVE
CDX Change of Director's Interest Notice
15/11/12
CDX Change of Director's Interest Notice
31/10/12
CDX Appendix 3B
31/10/12
CDX Change in substantial holding
30/10/12
CDX Results of Meeting
26/10/12
CDX Chairmans address to 2012 AGM
26/10/12
CDX Investor Presentation
22/10/12
CDX Appendix 4C - quarterly
18/10/12PRICE SENSITIVE
CDX US$3.2 million pharmaceutical trial contract
08/10/12PRICE SENSITIVE
CDX Annual Report to shareholders
26/09/12
CDX Notice of Annual General Meeting/Proxy Form
26/09/12
CDX New study finds arterial stiffness precedes hypertension
21/09/12
CDX Full Year Statutory Accounts
23/08/12PRICE SENSITIVE
CDX Change of Director's Interest Notice x 5
14/08/12
CDX US$1.1 million pharmaceutical contract
13/08/12PRICE SENSITIVE
CDX Appendix 3B
09/08/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
15.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $17.65M
Open High Low Value Volume
15.5¢ 17.5¢ 15.0¢ $134.7K 829.3K

Buyers (Bids)

No. Vol. Price($)
1 41542 14.5¢
 

Sellers (Offers)

Price($) Vol. No.
15.5¢ 62934 4
View Market Depth
Last trade - 11.35am 15/11/2024 (20 minute delay) ?
Last
14.5¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
15.0¢ 17.0¢ 14.5¢ 251365
Last updated 12.09pm 15/11/2024 ?
CDX (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.